Statistics for Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Total visits
| views | |
|---|---|
| Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial | 15 |
Total visits per month
| views | |
|---|---|
| octubre 2024 | 0 |
| noviembre 2024 | 0 |
| diciembre 2024 | 0 |
| enero 2025 | 0 |
| febrero 2025 | 0 |
| marzo 2025 | 0 |
| abril 2025 | 15 |
File Visits
| views | |
|---|---|
| 2025_Cahn_DoravirineIslatravir (1000.75 mg) Once-Daily Compared With BictegravirEmtricitabineTenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment 48-Week Results From a Phase 3, Randomized, Con.pdf | 2 |